Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Kyle C Molina"'
Autor:
Kyle C. Molina, Brandon J. Webb, Victoria Kennerley, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Neil R. Aggarwal, Adit A. Ginde
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on redu
Externí odkaz:
https://doaj.org/article/3e8ea79849a7468ea7505d78a68e5792
Autor:
Williams Monier Texidor, Matthew A. Miller, Kyle C. Molina, Martin Krsak, Barbara Calvert, Caitlin Hart, Marie Storer, Douglas N. Fish
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Oritavancin, a long-acting lipoglycopeptide approved for use in acute bacterial skin and skin structure infections, has limited data evaluating use in serious infections due to Gram-positive organisms. We aimed to assess the effec
Externí odkaz:
https://doaj.org/article/00072b40db7d4ed9aed1206bcfe94737
Autor:
Kyle C. Molina, Victoria Kennerley, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Neil R. Aggarwal, Adit A. Ginde
Publikováno v:
International Journal of Infectious Diseases, Vol 132, Iss , Pp 34-39 (2023)
ABSTRACT: Objectives: Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought to determine the real-world effectiveness of bebtelovimab during t
Externí odkaz:
https://doaj.org/article/9ed277ad61dd4335a7963ed7c8a1c772
Autor:
Sarah K. Wendel, Adane F. Wogu, Nichole E. Carlson, Laurel Beaty, Tellen D. Bennett, Kelly Bookman, David A. Mayer, Sean S. Michael, Kyle C. Molina, Jennifer L. Peers, Seth Russell, Richard D. Zane, Adit A. Ginde
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 5, Iss 1, Pp n/a-n/a (2024)
Abstract Objectives To evaluate whether subcutaneous neutralizing monoclonal antibody (mAb) treatment given in the emergency department (ED) setting was associated with reduced hospitalizations, mortality, and severity of disease when compared to non
Externí odkaz:
https://doaj.org/article/2ee2a76cab2c4689931484b0dc424f25
Autor:
Martin Krsak, Sias Scherger, Matthew A. Miller, Vincent Cobb, Brian T. Montague, Andrés F. Henao-Martínez, Kyle C. Molina
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 11 (2024)
Background: Severe gram-positive infections are frequent in people who inject drugs, and successful completion of treatment presents unique challenges in this population. Objectives: We aimed to evaluate the feasibility of a long-acting antibiotic, d
Externí odkaz:
https://doaj.org/article/976fc51597414a9dbb63fccff4c9da99
Autor:
Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M. Lagnf, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L.V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Kimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Marco R. Scipione, Jing J. Zhao, Paige Witucki, Michael J. Rybak
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 1 (2024)
ABSTRACT Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. ho
Externí odkaz:
https://doaj.org/article/c7670c6ad2ab4a279e5ee3917f0e0369
Autor:
Neil R. Aggarwal, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, David A. Mayer, Kyle C. Molina, Jennifer L. Peers, Seth Russell, Matthew K. Wynia, Adit A. Ginde
Publikováno v:
International Journal of Infectious Diseases, Vol 128, Iss , Pp 310-317 (2023)
ABSTRACT: Objectives: Sotrovimab effectively prevented progression to severe disease and mortality following infection with pre-Omicron SARS-CoV-2 variants. We sought to determine whether sotrovimab is similarly effective against SARS-CoV-2 Omicron v
Externí odkaz:
https://doaj.org/article/c23aa24013ca43e4b81a1fa46608b156
Autor:
Madison E. Salam, Meghan Jeffres, Kyle C. Molina, Matthew A. Miller, Misha Huang, Douglas N. Fish
Publikováno v:
Pharmacy, Vol 12, Iss 2, p 60 (2024)
Urinary tract infections (UTIs) are one of the most common infections and are frequently caused by Gram-negative organisms. The rise of resistant isolates has prompted evaluation of alternative therapies, including amoxicillin-clavulanate which has p
Externí odkaz:
https://doaj.org/article/ae6750bad01a47c69e5c15f2488efa38
Autor:
David J. Douin, Adane F. Wogu, Laurel E. Beaty, Nichole E. Carlson, Tellen D. Bennett, Neil R. Aggarwal, David A. Mayer, Toan C. Ong, Seth Russell, Jeffrey Steele, Jennifer L. Peers, Kyle C. Molina, Matthew K. Wynia, Adit A. Ginde
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Neutralizing monoclonal antibodies (mAbs) are highly effective in reducing hospitalization and mortality among early symptomatic COVID-19 patients in clinical trials and real-world data. While resistance to some mAbs has since eme
Externí odkaz:
https://doaj.org/article/9243363dc9f34305a5f57b6c977b0775
Autor:
Lilian Vargas Barahona, Kyle C. Molina, Laura C. Pedraza-Arévalo, Stefan Sillau, Alex Tagawa, Sias Scherger, Daniel B. Chastain, Leland Shapiro, Jose Tuells, Carlos Franco-Paredes, Kellie L. Hawkins, James P. Maloney, George R. Thompson, Andrés F. Henao-Martínez
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 10 (2023)
Background: HIV-negative patients have substantial mortality from Pneumocystis jirovecii pneumonia (PJP). We lack predictors of HIV-negative PJP-associated mortality. Objective: We aim to characterize the role of prior corticosteroid exposure in PJP-
Externí odkaz:
https://doaj.org/article/5d18c6113df44b35884b2044d443572d